Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis.
Saved in:
| Title: | Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis. |
|---|---|
| Authors: | Peters S; Oncology Department, Lausanne University Hospital, Lausanne, Switzerland. Electronic address: solange.peters@chuv.ch., Paz-Ares LG; Medical Oncology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain., Reck M; Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungenClinic Grosshansdorf, Grosshansdorf, Germany., Carbone DP; Department of Medical Oncology, The Ohio State University Comprehensive Cancer Center and the Pelotonia Institute for Immuno-Oncology, Columbus, Ohio., Brahmer JR; Department of Oncology, The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland., Borghaei H; Hematology and Oncology Department, Fox Chase Cancer Center, Temple Health, Philadelphia, Pennsylvania., Lu S; Department of Medical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China., O'Byrne KJ; Department of Medical Oncology, Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, Queensland, Australia., John T; Medical Oncology Department, Austin Hospital, Heidelberg, Victoria, Australia., Ciuleanu TE; Department of Medical Oncology, Institutul Oncologic Prof Dr Ion Chiricuţă and University of Medicine and Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania., Schenker M; Department of Medical Oncology, SF Nectarie Oncology Center, Craiova, Romania., Bernabe Caro R; Medical Oncology Department, Hospital Universitario Virgen Del Rocio, Instituto de Biomedicina de Seville, Seville, Spain., Nishio M; Department of Thoracic Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan., Cobo M; Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain., Lee JS; Department of Hematology/Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea., Zurawski B; Chemotherapy Department, Ambulatorium Chemioterapii, Bydgoszcz, Poland., Pluzanski A; Department of Lung Cancer and Chest Tumours, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Aoyama T; Clinical Development, Bristol Myers Squibb, Princeton, New Jersey., Tschaika M; Global Clinical Research Oncology, Bristol Myers Squibb, Princeton, New Jersey., Devas V; Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, New Jersey., Grootendorst DJ; Translational Sciences Oncology Imaging, Bristol Myers Squibb, Princeton, New Jersey., Ramalingam SS; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia. |
| Source: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2025 Jan; Vol. 20 (1), pp. 94-108. Date of Electronic Publication: 2024 Oct 04. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
